Posted by Roberto Muehlenkamp on November 19, 1999, at 11:57:42
In reply to Re: moclobemide, posted by Scott L. Schofield on November 17, 1999, at 20:29:17
> > I started taking Moclobemide about a month ago (first
> > 300 mg, then 450 mg. Everything went down the drain.
> > Not only did the depression not improve, it became a lot worse.
>
> > Has anyone experienced anything similar? I would very much like to know that
> > I'm not the only one who cannot take this drug.
>
>
> Yes !!!
>
> I thought I was the only one to experience this. I didn't want to post anything about it as not to dissuade anyone from trying it. Moclobemide made me feel worse than I ever have before of since. Thank God it has such a short half-live. Things got better within two days after discontinuation.
>
> I have one thought as to why it happened. I came across an abstract which concluded that moclobemide causes depletion of dopamine stores in certain areas of the brain. I don't remember which ones, but I believe they were limbic. I may go back to see if I can find it. For a long time I have suspected that my particular illness involves dopamine activity. This paper added another log to the fire.
>
>
> Thanks a lot for the post.
> I'm relieved to know that I wasn't the only one.
>
>
> - ScottHi Scott,
I found something that may go in the direction of your theory:
MOCLOBEMIDE
Humans now have the capacity to choose their own individual level of activity or inhibition of
the two primary monoamine oxidases. This does not quite enable the fine-tuning of
personality variables with the functional equivalent of a graphic equaliser. It still represents
a promising start. In MAO-inhibition, as in life, more is not always better. Excessive
dosages of l-deprenyl intake, for instance, may actually shorten, not increase, life expectancy
- at least in Parkinsonians if it's combined with l-dopa. And levels of above 80% inhibition of
MAO-A may lead to a sharp and possibly unwanted fall in dopamine synthesis. Repairing
Nature's niggardliness will be a priority for the decades ahead.
Source: http://www.neuropharmacology.com/By the way: As this source quotes Moclobemide as having been called the "gentle MAOI", I sent them my experience report. Maybe they'll reconsider on this qualification.
If you find your source, please let me know.
Kind regards,
Roberto
poster:Roberto Muehlenkamp
thread:15385
URL: http://www.dr-bob.org/babble/19991108/msgs/15535.html